Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference
Wednesday, September 9, 2026
8:45 a.m. ET - Prahlad Singh, president and chief executive officer

Morgan Stanley 24th Annual Global Healthcare Conference
Monday, September 14, 2026
8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

Baird’s 2026 Global Healthcare Conference
Tuesday, September 15, 2026
9:05 a.m. ET – Steve Willoughby, senior vice president, investor relations, ESG, and risk

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260811576461/en/

Investor Relations:
Steve Willoughby
[email protected]

Media Relations:
Chet Murray
(781) 462-5126
[email protected]

Source: Revvity

You May Also Be Interested In

• Integrated DNA Technologies Scientists Set New Performance Benchmark for CRISPR Off-Target Nomination
• Intentsify Unveils QuantumDemand™: AI-Powered Buying Group Activation at Scale
• Orvera AI Crosses 4.5 Million Annualized Custodian Outreach as Leading U.S. Record Retrieval Companies Move to AI-Run Operations